Chronic News and Research

RSS

UCSF to create first implantable device for patients with kidney failure

A $750,000 gift from the John and Marcia Goldman Foundation is spurring a UCSF-led effort to create the first implantable artificial kidney for patients with kidney failure.

3 Oct 2012

Respiratory infections provide urban asthma clue

Urban infants have a different pattern of viral respiratory illness from suburban infants, which could help explain why they are more likely to develop asthma, say US researchers.

2 Oct 2012

VOA News reports on Syria's health crisis in midst of civil war

"The United Nations estimates the civil war raging in Syria has left more than 2.5 million people in dire need of food, water, drugs and medical supplies," VOA News reports.

2 Oct 2012

Research report helps explain how macrophages accumulate triglycerides

A research report appearing in the Journal of Leukocyte Biology helps explain how specific immune cells, called macrophages, accumulate triglycerides to support their function.

2 Oct 2012

Omega-3 fatty acid supplements could slow key biological process linked to aging

Taking enough omega-3 fatty acid supplements to change the balance of oils in the diet could slow a key biological process linked to aging, new research suggests.

2 Oct 2012

Pediatric lower respiratory illness continues after hospital discharge

One-third of children hospitalized with severe lower respiratory illness have chronic moist cough a year after discharge, research shows.

1 Oct 2012

CBT ‘has no impact’ on juvenile fibromyalgia physical activity

Cognitive behavior therapy is not associated with increased physical activity levels in adolescents with juvenile fibromyalgia, research shows.

1 Oct 2012

WBC counts in diabetes risk prediction

An elevated white blood cell count in young men is an independent predictor for the development of diabetes in later life, suggest study findings.

1 Oct 2012

Participatory pay-for-performance improves primary care

Both quality of care measures and patient experience may be achieved through the introduction of a participatory pay-for-performance program, study findings indicate.

1 Oct 2012

Medication management, wound care part of new normal for caregivers

Today, AARP Public Policy Institute (PPI) and the United Hospital Fund (UHF) released a new report that finds 46 percent of family caregivers perform medical and nursing tasks for care recipients with multiple chronic physical and cognitive conditions.

1 Oct 2012

Five prominent surgeons receive Honorary Fellowship from ACS

Last night Honorary Fellowship in the American College of Surgeons (ACS) was awarded to five prominent surgeons from Japan, the Philippines, Mexico, England, and Belgium during Convocation ceremonies that preceded the official opening of the 2012 ACS Annual Clinical Congress.

1 Oct 2012

Most people completely unaware of aphasia

Most people are completely unaware of one of stroke's most common, debilitating but invisible impairments, according to the first awareness survey of its kind in Canada released today at the Canadian Stroke Congress.

1 Oct 2012

EC approves Sosei’s Seebri Breezhaler to treat COPD

Sosei Group Corporation confirms the information released today by Novartis that the European Commission has approved Seebri Breezhaler (glycopyrronium bromide) 44 mcg delivered dose (equivalent to 50 mcg glycopyrronium measured dose per capsule), as a once-daily inhaled maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

1 Oct 2012

Researchers uncover molecular and clinical role of irisin in humans

A research team led by Dr. Christos Mantzoros, MD, PhD, at Beth Israel Deaconess Medical Center, Harvard Medical School, has published new findings elucidating the molecular and clinical role of FNDC5/irisin in humans.

1 Oct 2012

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

Researchers identify how p110delta molecule controls the body's inflammatory responses

Researchers at Queen Mary, University of London have discovered how a key molecule controls the body's inflammatory responses. The molecule, known as p110delta, fine-tunes inflammation to avoid excessive reactions that can damage the organism.

1 Oct 2012

Study finds differences and similarities between iPSCs and cancer cells

UC Davis investigators have found new evidence that a promising type of stem cell now being considered for a variety of disease therapies is very similar to the type of cells that give rise to cancer. The findings suggest that although the cells -- known as induced pluripotent stem cells (iPSCs) -- show substantial promise as a source of replacement cells and tissues to treat injuries, disease and chronic conditions, scientists and physicians must move cautiously with any clinical use because iPSCs could also cause malignant cancer.

29 Sep 2012

U.N. meetings focus on improving nutrition among women, children

Political and private sector leaders met on Thursday at a High-Level Meeting on Scaling Up Nutrition, held in New York on the sidelines of the 67th U.N. General Assembly session, the U.N. News Centre reports.

29 Sep 2012

FDA approves Abbott’s HUMIRA to treat ulcerative colitis

Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough.

29 Sep 2012

BioTime forms new wholly owned subsidiary

BioTime, Inc., an Alameda-based company engaged in research and development of innovative new products in the field of regenerative medicine utilizing stem cells and related technology, announced today that it has formed a new wholly owned subsidiary, BioTime Acquisition Corporation, to pursue opportunities and acquire assets and businesses in the fields of stem cells and regenerative medicine.

29 Sep 2012